ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 445

Differing Specificities of Anticitrullinated Peptide/Protein Antibodies in Palindromic Rheumatism and Rheumatoid Arthritis: A Case-Control Study

Sonia Cabrera-Villalba1, María José Gomara2, Julio Ramirez1, Georgina Salvador3, Virginia Ruiz-Esquide1, M. Victoria Hernández1, José Inciarte-Mundo1, Andrea Cuervo1, Celia Saura1, Juan D. Cañete1, Isabel Haro2 and Raimon Sanmarti1, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain, 3Hospital Universitario Mutua Terrassa, Barcelona, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ACPA and palindromic rheumatism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Palindromic rheumatism (PR) may evolve to rheumatoid arthritis (RA), particularly in patients with citrullinated peptide/protein antibodies (ACPA), although a significant number of patients do not progress to RA in the long term. Differences in ACPA specificities have been shown between patients with established and preclinical RA. It is unclear whether ACPA specificities differ between patients with longstanding PR and RA. To determine whether there are differences in the recognition of epitopes between patients with longstanding PR and established RA by analysis of different ACPA specificities.

Methods: Case-control study. Cases: patients with pure PR, with no evolution to RA or other rheumatic disease at study entry. Controls: patients with established RA (ACR-87) matched by sex, disease duration and ACPA positivity (commercial CCP2 test [Eurodiagnostica]; NV<50U). ACPA specificity in sera was determined by ELISA test using a synthetic citrullinated peptide of fibrin as antigen: [Cit 630] α-Fibrin (617-631)(p18), two peptides of vimentin ([Cit 71] Vim (47-72)(p48), [Cit 64,69,71] Vim (47-72)(p55)) and one peptide of α-enolase: [Cys4,22 , Cit 9,15] Enolase (5-21)(CEP-1). The cut off for each ELISA test was established by ROC curves, with a specificity of 98% compared to a healthy population (blood donors, n=64). The presence and number of different ACPA specificities in the two groups was analyzed.

Results: We included 108 patients: 54 PR and 54 RA. 62.9% were female and 66.7% in both groups were CCP2 positive. No significant differences between groups in mean age (51.2±11.3 y vs 54.7±11.8 years) and disease duration (11.6±10.7 y vs. 8.3±6.1 years) were found. PR patients had a lower frequency of some ACPA specificities than RA, which was significant in the case of p 48 vimentin (1.9% RP vs. 14.8% AR, p: 0.015) and, especially, p 55 vimentin (PR 24.1% vs. 59.3% RA, p: <0.001). The mean number of ACPA specificities was lower in PR than in RA patients (0.9±0.9 PR vs. 1.4±1.03 AR, p=0.008). The percentage of sera with no ACPA specificity was greater in PR than in RA patients (42.6% vs 22.2% p= 0.02) (see Table). No differences between groups in the levels of different ACPA specificities were observed.

Conclusion: Patients with PR had a lower frequency of some antigenic specificities of ACPA in comparison with RA patients, especially in the case of citrullinated vimentin. PR patients also had a lower total number of specificities than RA patients. PR patients with fewer ACPA specificities and no recognition of citrullinated vimentin may have a better prognosis, without progression to RA.

Table: ACPA specificities in patients with PR and RA

PR n=54

RA n=54

p
CCP2, n,% 36 (66.7) 36 (66.7) 1
CCP2, levels 392.6 ± 527.6 487.4 ± 584.4 0.37
p18 α-fibrin n, % 19 (35.2) 26 (48.1) 0.17
CEP-1 enolase n, % 16 (29.6) 21 (38.9) 0.31
p48 vimentin n, % 1 (1.9) 8 (14.8) 0.015
p55 vimentin n, % 13 (24.1 32 (59.3) ‹0.001
Number of Vimentin specificities, mean  0.26 ± 0.4 0.74 ± 0.7 ‹0.001

Total number of ACPA specifies

0.91 ± 0.96

(min 0 – max 3)

1.43 ± 1.03

(min 0 – max 3)

0.008

Total number of ACPA specificites 

0

1

2

≥2

23 (42.6)

17 (31.5)

10 (18.5)

14 (25.9)

12 (22.2)

17 (31.5)

15 (27.8)

25 (46.3)

0.024

1

0.25

0.028


Disclosure:

S. Cabrera-Villalba,
None;

M. J. Gomara,
None;

J. Ramirez,
None;

G. Salvador,
None;

V. Ruiz-Esquide,
None;

M. V. Hernández,
None;

J. Inciarte-Mundo,
None;

A. Cuervo,
None;

C. Saura,
None;

J. D. Cañete,
None;

I. Haro,
None;

R. Sanmarti,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differing-specificities-of-anticitrullinated-peptideprotein-antibodies-in-palindromic-rheumatism-and-rheumatoid-arthritis-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology